ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2025
Immunohistochemical Classification of High-Grade Pancreatic Intraepithelial Neoplasia and Ductal Cancerization in Pancreatic Ductal Adenocarcinoma Using p53, SMAD4, and Mucin Expression.
Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunohistochemical Classification of High-Grade Pancreatic Intraepithelial Neoplasia and Ductal Cancerization in Pancreatic Ductal Adenocarcinoma Using p53, SMAD4, and Mucin Expression.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study was conducted to determine the frequency of high-grade pancreatic intraepithelial lesions (HG-PanIN) and the cancerization of ducts (COD), a phenomenon in which invasive cancer spreads within the pancreatic duct, and the differences between mucous profiles in pancreatic ductal adenocarcinoma. Immunohistochemistry for p53, SMAD4 and mucin was performed on 103 lesions in 97 cases. Carcinoma in situ (CIS) with p53 and SMAD4 staining that were different from invasive carcinoma were classified as HG-PanIN, while CIS with staining consistent with invasive carcinoma were classified as COD. CIS lesions were classified as 63 COD (61.2%) and 29 HG-PanIN (28.2%). The CODs consisted of 30 lesions (47.6%) with aberrant p53 and SMAD4, 26 lesions (41.3%) with aberrant p53, and 7 lesions (11.1%) with aberrant SMAD4. Fourteen HG-PanIN lesions (48.3%) had aberrant p53. MUC1 positivity was lower in COD (27 lesions; 42.9%) and HG-PanIN (16 lesions; 55.2%) than in invasive carcinoma (81 lesions; 83.5%) (p < 0.01). MUC6 was positive in 17 HG-PanIN lesions (58.6%)-higher than in invasive carcinoma (18 lesions; 18.6%) and COD (8 lesions; 12.7%) (p < 0.001). This study classified CIS as COD and HG-PanIN and found that the MUC6 expression of COD and HG-PanIN differed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.